Anti-CD40 antibodies and uses thereof
US11952427B2 · kind B2 · utility
0Cited by
49References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 15, 2022 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Mar 15, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.